MDSC: Markers, development, states, and unaddressed complexity DOI Creative Commons
Samarth Hegde, Andrew M. Leader, Miriam Mérad

et al.

Immunity, Journal Year: 2021, Volume and Issue: 54(5), P. 875 - 884

Published: May 1, 2021

Language: Английский

Inflammation and Cancer: Triggers, Mechanisms, and Consequences DOI Creative Commons
Florian R. Greten, Sergei I. Grivennikov

Immunity, Journal Year: 2019, Volume and Issue: 51(1), P. 27 - 41

Published: July 1, 2019

Language: Английский

Citations

2801
Targeting macrophages: therapeutic approaches in cancer DOI
Luca Cassetta, Jeffrey W. Pollard

Nature Reviews Drug Discovery, Journal Year: 2018, Volume and Issue: 17(12), P. 887 - 904

Published: Oct. 26, 2018

Language: Английский

Citations

1591
Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment DOI Creative Commons
Jonas Schulte-Schrepping, Nico Reusch, Daniela Paclik

et al.

Cell, Journal Year: 2020, Volume and Issue: 182(6), P. 1419 - 1440.e23

Published: Aug. 5, 2020

Language: Английский

Citations

1391
Tumor-Associated Macrophages in Tumor Immunity DOI Creative Commons

Yueyun Pan,

Yinda Yu,

Xiaojian Wang

et al.

Frontiers in Immunology, Journal Year: 2020, Volume and Issue: 11

Published: Dec. 3, 2020

Tumor-associated macrophages (TAMs) represent one of the main tumor-infiltrating immune cell types and are generally categorized into either two functionally contrasting subtypes, namely classical activated M1 alternatively M2 macrophages. The former typically exerts anti-tumor functions, including directly mediate cytotoxicity antibody-dependent cell-mediated (ADCC) to kill tumor cells; latter can promote occurrence metastasis cells, inhibit T response, angiogenesis, lead progression. Both have high degree plasticity thus be converted each other upon microenvironment changes or therapeutic interventions. As relationship between TAMs malignant tumors becoming clearer, become a promising target for developing new cancer treatment. In this review, we summarize origin TAMs, interaction with microenvironment, up-to-date treatment strategies targeting TAMs.

Language: Английский

Citations

1354
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity DOI Open Access
Filippo Veglia, Emilio Sanseviero, Dmitry I. Gabrilovich

et al.

Nature reviews. Immunology, Journal Year: 2021, Volume and Issue: 21(8), P. 485 - 498

Published: Feb. 1, 2021

Language: Английский

Citations

1286
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy DOI
Daniela Bruni, Helen K. Angell, Jérôme Galon

et al.

Nature reviews. Cancer, Journal Year: 2020, Volume and Issue: 20(11), P. 662 - 680

Published: Aug. 4, 2020

Language: Английский

Citations

1213
Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy DOI

Lei Xu,

Yu Lei,

Jin-ke Li

et al.

Cancer Letters, Journal Year: 2019, Volume and Issue: 470, P. 126 - 133

Published: Nov. 13, 2019

Language: Английский

Citations

1142
Advances in immunotherapy for hepatocellular carcinoma DOI Creative Commons
Bruno Sangro, Pablo Sarobe, Sandra Hervás‐Stubbs

et al.

Nature Reviews Gastroenterology & Hepatology, Journal Year: 2021, Volume and Issue: 18(8), P. 525 - 543

Published: April 13, 2021

Hepatocellular carcinoma (HCC) is a prevalent disease with progression that modulated by the immune system. Systemic therapy used in advanced stage and until 2017 consisted only of antiangiogenic tyrosine kinase inhibitors (TKIs). Immunotherapy checkpoint has shown strong anti-tumour activity subset patients combination anti-PDL1 antibody atezolizumab VEGF-neutralizing bevacizumab or will soon become standard care as first-line for HCC, whereas anti-PD1 agents nivolumab pembrolizumab are after TKIs several regions. Other strategies such adoptive T-cell transfer, vaccination virotherapy have not yet demonstrated consistent clinical activity. Major unmet challenges HCC immunotherapy discovery validation predictive biomarkers, advancing treatment to earlier stages disease, applying liver dysfunction more effective combinatorial sequential approaches. Combinations other systemic local treatments perceived most promising opportunities some already under evaluation large-scale trials. This Review provides up-to-date information on best use currently available immunotherapies therapeutic development. Immunotherapeutic interventions might be tools hepatocellular carcinoma. carcinoma, mechanisms response resistance,

Language: Английский

Citations

947
The lung microenvironment: an important regulator of tumour growth and metastasis DOI
Nasser K. Altorki, Geoffrey J. Markowitz, Dingcheng Gao

et al.

Nature reviews. Cancer, Journal Year: 2018, Volume and Issue: 19(1), P. 9 - 31

Published: Dec. 10, 2018

Language: Английский

Citations

911
Neutrophil diversity and plasticity in tumour progression and therapy DOI
Sébastien Jaillon, Andrea Ponzetta, Diletta Di Mitri

et al.

Nature reviews. Cancer, Journal Year: 2020, Volume and Issue: 20(9), P. 485 - 503

Published: July 21, 2020

Language: Английский

Citations

882